BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Targeting BCMA with therapeutics such as ADCs\, bispecific T-c
 ell engagers (BiTEs) and CAR-T therapies within Multiple Myeloma has huge
  potential. The race for an approval within the crowded BCMA space has be
 en hotly contested in recent years\, and despite GSK's ADC\, Blenrep\, ga
 ining approval in 2020 first\, BCMA-targeted CAR-T and BiTe therapies con
 tinue to find their place.\n\nWith such a well validated target\, rapid a
 dvances and growing excitement in the field\, the inaugural BCMA Targeted
  Therapies Summit is industry's first dedicated discussion and networking
  forum focused on bringing together the thought-leaders within the BCMA f
 ield to share the latest scientific progress and address the current chal
 lenges drug developers are facing.\n\nDeveloped with experts from Amgen\,
  Kite Pharma and Legend Bio and other leading organizations\, join 80+ of
  your peers and be part of this unique opportunity to engage in cross-ind
 ustry discussions. Hear from over 20 experts sharing preclinical data for
  next generation BCMA targeted therapies\, bringing in the patient perspe
 ctive and exploring efficacy of patient response from the clinic.\n
DTEND:20210623T160000
DTSTAMP:20260512T231941Z
DTSTART:20210621T090000
LOCATION:Online\, Online\, \,
SEQUENCE:0
SUMMARY:Targeting BCMA with therapeutics such as ADCs\, bispecific T-cell 
 engagers (BiTEs) and CAR-T therapies within Multiple Myeloma has huge pot
 ential. T...
UID:f1ad0d04-964e-40ba-b90e-d673101cbb19
END:VEVENT
END:VCALENDAR